H.C. Wainwright initiated coverage of Rapport Therapeutics (RAPP) with a Buy rating and $31 price target The firm believes RAP-219 could offer a “unique” clinical profile to address the unmet needs in epilepsy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP: